Novartis: Pulmonary Disease, Chronic Obstructive trials

The registry lists 117 Pulmonary Disease, Chronic Obstructive studies with Novartis as lead sponsor. 0 are open to participants now and 94 have results posted.

Phase 1 9Phase 2 26Phase 3 61Phase 4 24No phase 2(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT04268823Phase 2Results posted
• Dose-range Finding Efficacy and Safety Study for QBW251 in COPD PatientsCompletedNCT04072887Phase 2Results posted
• A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With EosinophiliaTerminatedNCT03810183Phase 2Results posted
• A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment AdherenceTerminatedNCT03379233Phase 3Results posted
• QVA Mechanistic Efficacy Study (Receptor Effects, Etc)CompletedNCT02634983Phase 4Results posted
• Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPDCompletedNCT02603393Phase 4Results posted
• Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler DevicesCompletedNCT02596009Phase 4Results posted
• A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD PatientsCompletedNCT02566031Phase 4Results posted
• Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02551224Not applicableResults posted
• Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient CohortCompletedNCT02516592Phase 4Results posted
• Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedNCT02487498Phase 3Results posted
• Efficacy and Safety Study of QVA149 in COPD PatientsCompletedNCT02487446Phase 3Results posted
• A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251CompletedNCT02449018Phase 2Results posted
• Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD PatientsCompletedNCT02442206Phase 4Results posted
• Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of ExacerbationsCompletedNCT02418468Phase 4Results posted
• A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPDCompletedNCT02371629Phase 4Results posted
• A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02233543Phase 4Results posted
• Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)CompletedNCT02202616Phase 4Results posted
• Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD PatientsCompletedNCT02125734Phase 4Results posted
• Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPDCompletedNCT02055352Phase 4Results posted
• Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.CompletedNCT01996319Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD RegimenCompletedNCT01985334Phase 4Results posted
• A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.TerminatedNCT01972776Phase 2Results posted
• Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPDCompletedNCT01959516Phase 4Results posted
• Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01922271Phase 4Results posted
• A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting BronchodilatorCompletedNCT01794780Phase 4Results posted
• QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)CompletedNCT01782326Phase 3Results posted
• Indacaterol EfectIveness In COPD Patients With Tuberculosis HistoryCompletedNCT01778062Phase 3Results posted
• A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.CompletedNCT01727141Phase 3Results posted
• Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD PatientsCompletedNCT01727024Phase 4Results posted
• NVA237 BID Versus Placebo Twelve-week Efficacy StudyCompletedNCT01715298Phase 3Results posted
• A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow LimitationCompletedNCT01712516Phase 3Results posted
• A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149CompletedNCT01709903Phase 3Results posted
• NVA237 Versus Placebo 12-week Efficacy StudyCompletedNCT01709864Phase 3Results posted
• Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.CompletedNCT01699685Phase 3Results posted
• Long Term Safety Study of NVA237 vs QAB149 in COPD PatientsCompletedNCT01697696Phase 3Results posted
• A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow LimitationCompletedNCT01682863Phase 3Results posted
• BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With CachexiaCompletedNCT01669174Phase 2Results posted
• Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01636076Phase 2Results posted
• Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01613326Phase 3Results posted
• Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow LimitationCompletedNCT01610037Phase 3Results posted
• Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01604278Phase 3Results posted
• The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01574651Phase 3Results posted
• Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01566604Phase 3Results posted
• Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)CompletedNCT01555138Phase 4Results posted
• Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01543828Phase 4Results posted
• Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01529632Phase 3Results posted
• Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01513460Phase 3Results posted
• The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01490125Phase 3Results posted
• QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01315249Phase 3Results posted
• Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01294787Phase 3Results posted
• Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01285492Phase 3Results posted
• 12-week Open-label Evaluation of Efficacy and Safety of IndacaterolCompletedNCT01232894Phase 3Results posted
• A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01202188Phase 3Results posted
• Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01154127Phase 3Results posted
• A Study to Assess the Long-term Safety of QVA149CompletedNCT01120717Phase 3Results posted
• Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) ExacerbationsCompletedNCT01120691Phase 3Results posted
• Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01119950Phase 2Results posted
• Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese PatientsCompletedNCT01119937Phase 3Results posted
• Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01089127Phase 3Results posted
• 12-week Efficacy of IndacaterolCompletedNCT01072448Phase 3Results posted
• Comparison of Efficacy of Indacaterol Versus Placebo Over 12 WeeksCompletedNCT01068600Phase 3Results posted
• Effect of Indacaterol on Inspiratory Capacity (IC)CompletedNCT01012765Phase 3Results posted
• A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus PlaceboCompletedNCT01005901Phase 3Results posted
• Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory CapacityCompletedNCT00999908Phase 3Results posted
• 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00929110Phase 3Results posted
• A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00900731Phase 3Results posted
• Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00877383Phase 3Results posted
• Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00876694Phase 3Results posted
• A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00856193Phase 2Results posted
• Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00846586Phase 3Results posted
• Exacerbation StudyCompletedNCT00845728Phase 3Results posted
• Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00821093Phase 3Results posted
• Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00794157Phase 3Results posted
• Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00792805Phase 3Results posted
• Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00677807Phase 3Results posted
• Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00669617Phase 3Results posted
• An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)CompletedNCT00636961Phase 2Results posted
• Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00624286Phase 3Results posted
• A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00622635Phase 3Results posted
• The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT00620022Phase 3Results posted
• A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active ControlCompletedNCT00615459Phase 3Results posted
• Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00615030Phase 3Results posted
• Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00581945Phase 1/2Results posted
• Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00570778Phase 2Results posted
• Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active ControlCompletedNCT00567996Phase 3Results posted
• Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00558285Phase 2Results posted
• A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00557466Phase 2Results posted
• Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and SalmeterolCompletedNCT00531050Phase 2Results posted
• Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT00510510Phase 2Results posted
• Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator TiotropiumCompletedNCT00501852Phase 2Results posted
• 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00463567Phase 2/3Results posted
• Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00403845Phase 2Results posted
• Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active ControlCompletedNCT00393458Phase 3Results posted
• Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPDCompletedNCT04882124Phase 2
• Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPDCompletedNCT02123199
• Study to Evaluate the Impact of the "PROactive Telecoaching Program" on Physical Activity in Patients With COPD.WithdrawnNCT01992081Phase 4
• A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPDWithdrawnNCT01860066Phase 3
• Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.WithdrawnNCT01837927Phase 3
• A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPDWithdrawnNCT01834885Phase 3